Clinuvel Pharmaceuticals Ltd (CUVL) reported fiscal 2026 cash flows and clinical updates for the year ended June 30, 2026. Net cash provided by operating activities was $12,906,429, compared with $27,295,554 in fiscal 2025; net cash decreased $4,148,257. Investing activities used $25,636,672, and financing activities used $1,669,075.
The Australian Taxation Office required the company to pay a minimum of 85% of estimated fiscal 2026 income tax during that year; upfront payments were $5.3 million. The company described a $9.2 million unrealized foreign-currency measurement loss as a balance-date adjustment, not a real financial loss. Management believes existing cash and expected SCENESSE® sales will fund at least four years of current operating and capital needs within projected operations.
CUV105, an open-label Phase III study of SCENESSE® with adjunct NB-UVB for vitiligo, enrolled 210 adult and adolescent patients; topline results are expected in December 2026. Clinuvel is finalizing the planned Phase III CUV107 study and, subject to confirmation, anticipates enrolling 300 patients and starting in November 2026. Commencement remains subject to regulatory discussions, and CUV107’s timing depends on CUV105 results.
Clinuvel Pharmaceuticals Ltd filed a dossier seeking marketing authorisation for NEURACTHEL® Instant (tetracosactide), its second pharmaceutical product, with national European regulators through the decentralised procedure. If approved, the prescription product could be commercialised in up to three initial EU Member States.
The procedure is intended to take 300 days after dossier validation, excluding potential clock-stop periods, with a final position at day 270. Clinuvel said it expects validation and first formal feedback in around four months. NEURACTHEL® Instant is not currently approved in any country. Further submissions to the UK and other EU Member States are being evaluated, and a timeline for a U.S. FDA filing is under review.
Clinuvel Pharmaceuticals Limited (CUVL) furnished an Appendix 3H notification titled “Notification of cessation of securities,” which it filed with the Australian Securities Exchange on October 15, 2026.
Clinuvel Pharmaceuticals Ltd filed its Notice of Annual General Meeting and Proxy Form with the Australian Securities Exchange on October 1, 2026.
Clinuvel Pharmaceuticals Ltd announced that three CUV105 vitiligo cases are being presented at EADV, with all participants showing follicular repigmentation after SCENESSE® and adjunct narrowband ultraviolet B (NB-UVB) phototherapy. Two cases were new, and one had been presented previously. The participants completed seven SCENESSE® implants and NB-UVB twice weekly for 20 weeks, with up to 41 sessions, then were followed for up to 24 weeks after therapy ended. Clinuvel reported treatment was well tolerated and spontaneous repigmentation was observed in all three participants during follow-up. Top-line CUV105 results are due in December 2026.
Clinuvel Pharmaceuticals Ltd (CUVL) submitted a Form 6-K as a foreign private issuer, forwarding materials it filed with the Australian Securities Exchange on August 27, 2026. The submission packages the company’s annual report, corporate governance disclosures, an Appendix 4G, an investor presentation, and several press releases as exhibits.
Clinuvel Pharmaceuticals Ltd (CUVL) reports that it will release its financial results for the year ending 30 June 2026 on 27 August 2026. Management will host an investor and analyst webinar the same day from 18:00 to 18:30 AEST to review the results.
The webinar will be accessible online via Zoom, with participants able to submit questions during registration and throughout the event. The company also reiterates its focus on melanocortin-based therapies, including its lead approved treatment SCENESSE for erythropoietic protoporphyria across several major regions.
Clinuvel Pharmaceuticals reports progress on its VLRX-L controlled-release injectable liquid peptide platform. After pre-clinical evaluation of four candidate formulations, one formulation showed a superior release profile over the targeted delivery window, with lower peak plasma levels and sustained drug levels over the dosing period. The company’s Singapore-based RD&I Centre, VALLAURIX, is now refining this lead candidate. Pending final optimisation and results, further pre-clinical studies are planned for Q1 2027, and manufacturing scale-up is being scoped. The initial focus for VLRX-L is melanocortin peptides, aimed at enabling flexible, individualised dosing for different patient populations.
Clinuvel Pharmaceuticals provided a commercial update on vitiligo, outlining benchmarks for current therapies and the development of its lead melanocortin drug SCENESSE® (afamelanotide) with adjunct narrowband UVB (NB-UVB) as a systemic repigmentation approach for patients with extensive disease affecting at least 10% of body surface area.
The update reviews published response rates for NB-UVB and topical and oral Janus kinase (JAK) inhibitors, then notes early CUV105 data showing visible, lasting repigmentation in 12 SCENESSE® plus NB-UVB case reports and prior trials where the combination outperformed NB-UVB alone, while afamelanotide monotherapy was ineffective. Clinuvel states it has reinforced supply chains, expanded North American infrastructure, engaged more than 100 prospective Specialty Centers, anticipates CUV105 topline results in December 2026, and indicates the anticipated start of pivotal CUV107 in November 2026.